Literature DB >> 5019090

Isoniazid chemoprophylaxis of tuberculosis.

D Jenkins, F F Davidson.   

Abstract

A major step toward the eradication of tuberculosis in the United States has been the use of isoniazid for chemoprophylaxis in certain persons who have positive tuberculin skin tests but no other evidence of active infection. Chemical trials have demonstrated the effectiveness of chemoprophylaxis in groups where there is a relatively high risk of active tuberculosis. However, only the practicing physician can identify and offer chemoprophylaxis to many other susceptible persons. Even if the patient is a candidate for isoniazid, the risk of developing tuberculosis must be weighed against the cost and possible adverse effects of the drug. If isoniazid is given, the physician must be alert to the signs of possible drug toxicity. If isoniazid is not given, he must anticipate the development of active tuberculosis in susceptible persons.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5019090      PMCID: PMC1518343     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  19 in total

1.  THE EPIDEMIOLOGIC BONUS.

Authors:  S H FEREBEE; C E PALMER
Journal:  Am Rev Respir Dis       Date:  1965-01

2.  The effects of early isoniazid treatment in experimental guinea pig tuberculosis.

Authors:  L R PEIZER; A D CHAVES; D WIDELOCK
Journal:  Am Rev Tuberc       Date:  1957-11

3.  Studies on prevention of experimental tuberculosis with isoniazid. II. Effects of different dosage regimens.

Authors:  S H FEREBEE; L HOPWOOD; C E PALMER
Journal:  Am Rev Tuberc       Date:  1956-12

4.  The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children.

Authors:  E M LINCOLN
Journal:  Am Rev Tuberc       Date:  1954-05

5.  The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis.

Authors:  F W MOUNT; S H FEREBEE
Journal:  Am Rev Respir Dis       Date:  1962-06

Review 6.  Controlled chemoprophylaxis trials in tuberculosis. A general review.

Authors:  S H Ferebee
Journal:  Bibl Tuberc       Date:  1970

7.  Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.

Authors:  L Scharer; J P Smith
Journal:  Ann Intern Med       Date:  1969-12       Impact factor: 25.391

8.  Prophylactic effect of isoniazid in young tuberculin reactors.

Authors:  F J Curry
Journal:  N Engl J Med       Date:  1967-09-14       Impact factor: 91.245

9.  Isoniazid and impairment of memory.

Authors:  K Torning; P Z Olsen
Journal:  Dis Chest       Date:  1968-06

10.  Drug-induced lupus syndrome. A case report implicating isoniazid.

Authors:  T E Hothersall; A G Mowat; J J Duthie; W R Alexander
Journal:  Scott Med J       Date:  1967-07       Impact factor: 0.729

View more
  5 in total

1.  Isoniazid chemoprophylaxis.

Authors:  F F Davidson
Journal:  Calif Med       Date:  1972-11

2.  JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.

Authors:  Keiichi Mikasa; Nobuki Aoki; Yosuke Aoki; Shuichi Abe; Satoshi Iwata; Kazunobu Ouchi; Kei Kasahara; Junichi Kadota; Naoki Kishida; Osamu Kobayashi; Hiroshi Sakata; Masahumi Seki; Hiroki Tsukada; Yutaka Tokue; Fukumi Nakamura-Uchiyama; Futoshi Higa; Koichi Maeda; Katsunori Yanagihara; Koichiro Yoshida
Journal:  J Infect Chemother       Date:  2016-06-15       Impact factor: 2.211

3.  Four months of rifampicin monotherapy for latent tuberculosis infection in children.

Authors:  Chi Eun Oh; Dick Menzies
Journal:  Clin Exp Pediatr       Date:  2021-10-29

4.  Latent Tuberculosis Infection Screening and Treatment in Congregate Settings (TB FREE COREA): Demographic Profiles of Interferon-Gamma Release Assay Cohort.

Authors:  Hyung Woo Kim; Jinsoo Min; Joon Young Choi; Ah Young Shin; Jun-Pyo Myong; Yunhee Lee; Hyeon Woo Yim; Hyunsuk Jeong; Sanghyuk Bae; Eunhye Shim; Hyekyung In; Chaemin Chun; Gahee Kim; Ji Young Kang; Sung-Soon Lee; Jae Seuk Park; Ju Sang Kim
Journal:  J Korean Med Sci       Date:  2021-09-13       Impact factor: 2.153

Review 5.  Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy.

Authors:  Hyung Woo Kim; Ju Sang Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2018-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.